VX 135

Drug Profile

VX 135

Alternative Names: ALS-002200; ALS-2200; VX-135

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alios BioPharma
  • Developer Alios BioPharma; Bristol-Myers Squibb; Vertex Pharmaceuticals
  • Class Antivirals; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 May 2014 Vertex Pharmaceuticals and Bristol-Myers Squibb complete a phase II trial in Hepatitis C (Combination therapy, Treatment-naive) in New Zealand (NCT01842451)
  • 01 May 2014 Discontinued - Phase-I for Hepatitis C (Treatment-naive) in France and Romania (PO)
  • 01 May 2014 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in USA, Moldova and New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top